Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers-Reference-Cited by-同舟云学术

Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers

Published:2020-12-19 Issue:3 Volume:63 Page:311-319
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle & Nerve

Author:

Chen Er¹,Dixon Stacy²,Naik Rupali³,Noone Josh M.⁴,Buchenberger J. Daniel⁴^ORCID,Whitmire Sarah M.⁴,Mills Rosalina⁴,Arnold William⁵

Affiliation:

1. Genentech Inc San Francisco California USA

2. Department of Neurology University of Colorado School of Medicine Aurora Colorado USA

3. Noesis Healthcare Technologies, Inc San Francisco California USA

4. Ipsos Healthcare New York New York USA

5. Department of Neurology The Ohio State University Columbus Ohio USA

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Clinical Neurology,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27116

Reference24 articles.

1. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States

2. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics

3. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care

4. Food and Drug Administration.FDA approves first drug for spinal muscular atrophy.2016.https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm534611.htm. Accessed June 20 2019.

5. Cure SMA.AveXis files for FDA approval of gene therapy for spinal muscular atrophy type I.2018.http://www.curesma.org/news/avexis-fda-approval-type-i.htmlAccessed June 20 2019.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical perspectives: Treating spinal muscular atrophy;Molecular Therapy;2024-08

2. Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis;Advances in Therapy;2024-05-06

3. Global Risdiplam Compassionate Use Program for Patients with Type 1 or 2 Spinal Muscular Atrophy;Clinical Therapeutics;2024-04

4. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment;Journal of Neurology;2024-02-15

5. A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy;Muscle & Nerve;2023-12